Key Highlights

  • BlossomHill Therapeutics (Nasdaq: BLSM) reported updated Phase 1/2 SOLARA results for oral OMNI-EGFR candidate BH-30643.
  • Across 40 subjects with EGFR C797S-positive NSCLC, the therapy produced a 45% objective response rate and 88% disease control rate.
  • BH-30643 holds FDA Fast Track Designation and targets a resistance setting with no approved options.
  • Shares of BlossomHill Therapeutics (Nasdaq: BLSM) closed up 18% at $26.25.

SOLARA Data Show Meaningful Response Rates

BlossomHill Therapeutics (Nasdaq: BLSM) reported updated results from its Phase 1/2 SOLARA trial evaluating BH-30643, an oral OMNI-EGFR candidate, in patients with EGFR C797S-positive non-small cell lung cancer. Over a median follow-up of 6.9 months across 40 subjects, the therapy delivered a 45% objective response rate and an 88% disease control rate.

Addressing a Resistance Gap

The data come with a favorable tolerability profile and FDA Fast Track designation already in hand. BH-30643 is being developed for patients who have progressed on third-generation EGFR inhibitors and developed C797S resistance mutations, a setting where no approved targeted therapies currently exist. BlossomHill Therapeutics (Nasdaq: BLSM) is advancing the candidate as a potential option for this underserved patient population.

Shares Climb on Data

Shares of BlossomHill Therapeutics (Nasdaq: BLSM) closed up 18% at $26.25 following the update, as investors responded to the response and disease control rates in a resistance setting that currently lacks approved targeted treatments.

What is BH-30643?

An oral OMNI-EGFR candidate being developed by BlossomHill Therapeutics for EGFR C797S-positive non-small cell lung cancer.

What did the SOLARA trial show?

A 45% objective response rate and 88% disease control rate across 40 subjects over a median 6.9-month follow-up.

What regulatory status does BH-30643 have?

FDA Fast Track designation.